Advocacy Tools
Advocacy materials and tools developed by hepCoalition and partner organizations that can be adapted and used by advocates for local campaigns in their own contexts. Includes training materials, community monitoring/data collection, and graphics.
Materials in this section
Medicines for HIV, Viral Hepatitis, and STIs in LMICs: Forecasts of Global Demand for 2022-2026
WHO releases a report jointly presenting medicines forecasts across three disease areas in recognition of the benefits of addressing HIV, viral hepatitis and STIs in a coordinated manner. More
2024 Global Hepatitis Report
WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day. Viral hepatitis is the second leading infectious cause of death globally. More
EuroNPUD Technical Briefing: Community-Led Approaches to HCV Testing, Treatment and Care
A Technical Briefing includes two case studies that spotlight successful community-led approaches in Portugal and Norway, offering valuable insights into the effectiveness of integrating peer-led initiatives into HCV healthcare strategies. More
Eliminating Hepatitis C in Europe: Report on Policy Implementation for People Who Inject Drugs
C-EHRN releases a report focusing on the availability of and access to interventions that constitute the HCV continuum of care specific for people who inject drugs in 35 European cities. More
Joint Report on Drug Consumption Rooms in Europe
A report, released by EMCDDA and C-EHRN, presents the latest overview on drug consumption rooms in Europe. More
Global State of Harm Reduction: 2023 Update to Key Data
The 2023 update summarises some of the key developments in harm reduction and drug policy since the launch of the 8th edition of the Global State of Harm Reduction report in November 2022. More
HCV Market Intelligence Report 2023
CHAI releases the third issue of the HCV Market Intelligence Report on HCV diagnostics and drugs in LMICs, including for the first time preliminary insights into harm reduction commodities. More
NOW is the Time for Hepatitis C Virus Elimination
A publication, released by Treatment Action Group, makes the case for prioritizing HCV elimination in the United States, in keeping with the Viral Hepatitis National Strategic Plan: 2021 – 2025. More
Beyond Intellectual Property: Why Is Generic Treatment for HCV Still So Hard to Get
An article in 2023 issue of TAGline explores how to reimagine HCV elimination strategies now that intellectual property is no longer restricting access to generic cures. More
Long-Acting Therapies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
Treatment Action Group releases a trials tracker providing a compilation of ongoing clinical trials on long-acting treatments for HCV, malaria, and opioid use and overdose prevention. More
